APO Research
Talk to an analyst

APO RESEARCH · REPORT

Mycoplasma Pneumoniae Antibodies

Compare research editions
View pricing & licenses

Selected research

Industry Research

Mycoplasma Pneumoniae Antibodies Industry Research Report 2026

19 December 2025136 pages

Choose your research edition.

Industry ResearchMycoplasma Pneumoniae Antibodies Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Mycoplasma Pneumoniae Antibodies Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Mycoplasma Pneumoniae Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mycoplasma Pneumoniae Antibodies Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Mycoplasma Pneumoniae Antibodies Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Mycoplasma Pneumoniae Antibodies market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Mycoplasma Pneumoniae Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Mycoplasma Pneumoniae Antibodies is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Mycoplasma Pneumoniae Antibodies is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Mycoplasma Pneumoniae Antibodies include Abbexa Ltd, Abcam, Abnova Corporation, American Research Products Inc., Bio-Rad, Biorbyt, Creative Biolabs, EastCoast Bio and Fitzgerald Industries International, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Mycoplasma Pneumoniae Antibodies market in terms of revenue (US$ million) and, where applicable, sales volume (L), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/L) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Mycoplasma Pneumoniae Antibodies Market by Company

Abbexa Ltd

Abcam

Abnova Corporation

American Research Products Inc.

Bio-Rad

Biorbyt

Creative Biolabs

EastCoast Bio

Fitzgerald Industries International

GeneTex

GRP GmbH

LifeSpan BioSciences

MyBioSource.com

Novus Biologicals

OriGene Technologies

ProSci, Inc

United States Biological

Thermo Fisher Scientific

Mycoplasma Pneumoniae Antibodies Segment by Type

Polyclonal

Monoclonal

Mycoplasma Pneumoniae Antibodies Segment by Application

Research Institutes

Hospitals & Diagnostic Laboratories

Pharmaceutical & Biotechnology

Others

Mycoplasma Pneumoniae Antibodies Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mycoplasma Pneumoniae Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mycoplasma Pneumoniae Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mycoplasma Pneumoniae Antibodies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Mycoplasma Pneumoniae Antibodies manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Mycoplasma Pneumoniae Antibodies by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Mycoplasma Pneumoniae Antibodies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Mycoplasma Pneumoniae Antibodies Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Mycoplasma Pneumoniae Antibodies Sales (L) of Manufacturers (2021-2026) Table 7. Global Mycoplasma Pneumoniae Antibodies Sales Market Share by Manufacturers (2021-2026) Table 8. Global Mycoplasma Pneumoniae Antibodies Revenue of Manufacturers (2021-2026) Table 9. Global Mycoplasma Pneumoniae Antibodies Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Mycoplasma Pneumoniae Antibodies Average Price (US$/L) of Manufacturers (2021-2026) Table 11. Global Mycoplasma Pneumoniae Antibodies Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Mycoplasma Pneumoniae Antibodies, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Mycoplasma Pneumoniae Antibodies, Product Type & Application Table 14. Global Mycoplasma Pneumoniae Antibodies Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Mycoplasma Pneumoniae Antibodies by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Abbexa Ltd Company Information Table 19. Abbexa Ltd Business Overview Table 20. Abbexa Ltd Mycoplasma Pneumoniae Antibodies Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 21. Abbexa Ltd Mycoplasma Pneumoniae Antibodies Product Portfolio Table 22. Abbexa Ltd Recent Developments Table 23. Abcam Company Information Table 24. Abcam Business Overview Table 25. Abcam Mycoplasma Pneumoniae Antibodies Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 26. Abcam Mycoplasma Pneumoniae Antibodies Product Portfolio Table 27. Abcam Recent Developments Table 28. Abnova Corporation Company Information Table 29. Abnova Corporation Business Overview Table 30. Abnova Corporation Mycoplasma Pneumoniae Antibodies Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 31. Abnova Corporation Mycoplasma Pneumoniae Antibodies Product Portfolio Table 32. Abnova Corporation Recent Developments Table 33. American Research Products Inc. Company Information Table 34. American Research Products Inc. Business Overview Table 35. American Research Products Inc. Mycoplasma Pneumoniae Antibodies Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 36. American Research Products Inc. Mycoplasma Pneumoniae Antibodies Product Portfolio Table 37. American Research Products Inc. Recent Developments Table 38. Bio-Rad Company Information Table 39. Bio-Rad Business Overview Table 40. Bio-Rad Mycoplasma Pneumoniae Antibodies Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 41. Bio-Rad Mycoplasma Pneumoniae Antibodies Product Portfolio Table 42. Bio-Rad Recent Developments Table 43. Biorbyt Company Information Table 44. Biorbyt Business Overview Table 45. Biorbyt Mycoplasma Pneumoniae Antibodies Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 46. Biorbyt Mycoplasma Pneumoniae Antibodies Product Portfolio Table 47. Biorbyt Recent Developments Table 48. Creative Biolabs Company Information Table 49. Creative Biolabs Business Overview Table 50. Creative Biolabs Mycoplasma Pneumoniae Antibodies Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 51. Creative Biolabs Mycoplasma Pneumoniae Antibodies Product Portfolio Table 52. Creative Biolabs Recent Developments Table 53. EastCoast Bio Company Information Table 54. EastCoast Bio Business Overview Table 55. EastCoast Bio Mycoplasma Pneumoniae Antibodies Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 56. EastCoast Bio Mycoplasma Pneumoniae Antibodies Product Portfolio Table 57. EastCoast Bio Recent Developments Table 58. Fitzgerald Industries International Company Information Table 59. Fitzgerald Industries International Business Overview Table 60. Fitzgerald Industries International Mycoplasma Pneumoniae Antibodies Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 61. Fitzgerald Industries International Mycoplasma Pneumoniae Antibodies Product Portfolio Table 62. Fitzgerald Industries International Recent Developments Table 63. GeneTex Company Information Table 64. GeneTex Business Overview Table 65. GeneTex Mycoplasma Pneumoniae Antibodies Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 66. GeneTex Mycoplasma Pneumoniae Antibodies Product Portfolio Table 67. GeneTex Recent Developments Table 68. GRP GmbH Company Information Table 69. GRP GmbH Business Overview Table 70. GRP GmbH Mycoplasma Pneumoniae Antibodies Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 71. GRP GmbH Mycoplasma Pneumoniae Antibodies Product Portfolio Table 72. GRP GmbH Recent Developments Table 73. LifeSpan BioSciences Company Information Table 74. LifeSpan BioSciences Business Overview Table 75. LifeSpan BioSciences Mycoplasma Pneumoniae Antibodies Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 76. LifeSpan BioSciences Mycoplasma Pneumoniae Antibodies Product Portfolio Table 77. LifeSpan BioSciences Recent Developments Table 78. MyBioSource.com Company Information Table 79. MyBioSource.com Business Overview Table 80. MyBioSource.com Mycoplasma Pneumoniae Antibodies Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 81. MyBioSource.com Mycoplasma Pneumoniae Antibodies Product Portfolio Table 82. MyBioSource.com Recent Developments Table 83. Novus Biologicals Company Information Table 84. Novus Biologicals Business Overview Table 85. Novus Biologicals Mycoplasma Pneumoniae Antibodies Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 86. Novus Biologicals Mycoplasma Pneumoniae Antibodies Product Portfolio Table 87. Novus Biologicals Recent Developments Table 88. OriGene Technologies Company Information Table 89. OriGene Technologies Business Overview Table 90. OriGene Technologies Mycoplasma Pneumoniae Antibodies Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 91. OriGene Technologies Mycoplasma Pneumoniae Antibodies Product Portfolio Table 92. OriGene Technologies Recent Developments Table 93. ProSci, Inc Company Information Table 94. ProSci, Inc Business Overview Table 95. ProSci, Inc Mycoplasma Pneumoniae Antibodies Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 96. ProSci, Inc Mycoplasma Pneumoniae Antibodies Product Portfolio Table 97. ProSci, Inc Recent Developments Table 98. United States Biological Company Information Table 99. United States Biological Business Overview Table 100. United States Biological Mycoplasma Pneumoniae Antibodies Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 101. United States Biological Mycoplasma Pneumoniae Antibodies Product Portfolio Table 102. United States Biological Recent Developments Table 103. Thermo Fisher Scientific Company Information Table 104. Thermo Fisher Scientific Business Overview Table 105. Thermo Fisher Scientific Mycoplasma Pneumoniae Antibodies Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 106. Thermo Fisher Scientific Mycoplasma Pneumoniae Antibodies Product Portfolio Table 107. Thermo Fisher Scientific Recent Developments Table 108. Global Mycoplasma Pneumoniae Antibodies Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 109. Global Mycoplasma Pneumoniae Antibodies Sales by Region (2021-2026) & (L) Table 110. Global Mycoplasma Pneumoniae Antibodies Sales Market Share by Region (2021-2026) Table 111. Global Mycoplasma Pneumoniae Antibodies Sales by Region (2027-2032) & (L) Table 112. Global Mycoplasma Pneumoniae Antibodies Sales Market Share by Region (2027-2032) Table 113. Global Mycoplasma Pneumoniae Antibodies Revenue by Region (2021-2026) & (US$ Million) Table 114. Global Mycoplasma Pneumoniae Antibodies Revenue Market Share by Region (2021-2026) Table 115. Global Mycoplasma Pneumoniae Antibodies Revenue by Region (2027-2032) & (US$ Million) Table 116. Global Mycoplasma Pneumoniae Antibodies Revenue Market Share by Region (2027-2032) Table 117. North America Mycoplasma Pneumoniae Antibodies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. North America Mycoplasma Pneumoniae Antibodies Sales by Country (2021-2026) & (L) Table 119. North America Mycoplasma Pneumoniae Antibodies Sales by Country (2027-2032) & (L) Table 120. North America Mycoplasma Pneumoniae Antibodies Revenue by Country (2021-2026) & (US$ Million) Table 121. North America Mycoplasma Pneumoniae Antibodies Revenue by Country (2027-2032) & (US$ Million) Table 122. Europe Mycoplasma Pneumoniae Antibodies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Europe Mycoplasma Pneumoniae Antibodies Sales by Country (2021-2026) & (L) Table 124. Europe Mycoplasma Pneumoniae Antibodies Sales by Country (2027-2032) & (L) Table 125. Europe Mycoplasma Pneumoniae Antibodies Revenue by Country (2021-2026) & (US$ Million) Table 126. Europe Mycoplasma Pneumoniae Antibodies Revenue by Country (2027-2032) & (US$ Million) Table 127. Asia Pacific Mycoplasma Pneumoniae Antibodies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Asia Pacific Mycoplasma Pneumoniae Antibodies Sales by Country (2021-2026) & (L) Table 129. Asia Pacific Mycoplasma Pneumoniae Antibodies Sales by Country (2027-2032) & (L) Table 130. Asia Pacific Mycoplasma Pneumoniae Antibodies Revenue by Country (2021-2026) & (US$ Million) Table 131. Asia Pacific Mycoplasma Pneumoniae Antibodies Revenue by Country (2027-2032) & (US$ Million) Table 132. South America Mycoplasma Pneumoniae Antibodies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. South America Mycoplasma Pneumoniae Antibodies Sales by Country (2021-2026) & (L) Table 134. South America Mycoplasma Pneumoniae Antibodies Sales by Country (2027-2032) & (L) Table 135. South America Mycoplasma Pneumoniae Antibodies Revenue by Country (2021-2026) & (US$ Million) Table 136. South America Mycoplasma Pneumoniae Antibodies Revenue by Country (2027-2032) & (US$ Million) Table 137. Middle East and Africa Mycoplasma Pneumoniae Antibodies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Middle East and Africa Mycoplasma Pneumoniae Antibodies Sales by Country (2021-2026) & (L) Table 139. Middle East and Africa Mycoplasma Pneumoniae Antibodies Sales by Country (2027-2032) & (L) Table 140. Middle East and Africa Mycoplasma Pneumoniae Antibodies Revenue by Country (2021-2026) & (US$ Million) Table 141. Middle East and Africa Mycoplasma Pneumoniae Antibodies Revenue by Country (2027-2032) & (US$ Million) Table 142. Global Mycoplasma Pneumoniae Antibodies Sales by Type (2021-2026) & (L) Table 143. Global Mycoplasma Pneumoniae Antibodies Sales by Type (2027-2032) & (L) Table 144. Global Mycoplasma Pneumoniae Antibodies Sales Market Share by Type (2021-2026) Table 145. Global Mycoplasma Pneumoniae Antibodies Sales Market Share by Type (2027-2032) Table 146. Global Mycoplasma Pneumoniae Antibodies Revenue by Type (2021-2026) & (US$ Million) Table 147. Global Mycoplasma Pneumoniae Antibodies Revenue by Type (2027-2032) & (US$ Million) Table 148. Global Mycoplasma Pneumoniae Antibodies Revenue Market Share by Type (2021-2026) Table 149. Global Mycoplasma Pneumoniae Antibodies Revenue Market Share by Type (2027-2032) Table 150. Global Mycoplasma Pneumoniae Antibodies Price by Type (2021-2026) & (US$/L) Table 151. Global Mycoplasma Pneumoniae Antibodies Price by Type (2027-2032) & (US$/L) Table 152. Global Mycoplasma Pneumoniae Antibodies Sales by Application (2021-2026) & (L) Table 153. Global Mycoplasma Pneumoniae Antibodies Sales by Application (2027-2032) & (L) Table 154. Global Mycoplasma Pneumoniae Antibodies Sales Market Share by Application (2021-2026) Table 155. Global Mycoplasma Pneumoniae Antibodies Sales Market Share by Application (2027-2032) Table 156. Global Mycoplasma Pneumoniae Antibodies Revenue by Application (2021-2026) & (US$ Million) Table 157. Global Mycoplasma Pneumoniae Antibodies Revenue by Application (2027-2032) & (US$ Million) Table 158. Global Mycoplasma Pneumoniae Antibodies Revenue Market Share by Application (2021-2026) Table 159. Global Mycoplasma Pneumoniae Antibodies Revenue Market Share by Application (2027-2032) Table 160. Global Mycoplasma Pneumoniae Antibodies Price by Application (2021-2026) & (US$/L) Table 161. Global Mycoplasma Pneumoniae Antibodies Price by Application (2027-2032) & (US$/L) Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. Mycoplasma Pneumoniae Antibodies Distributors List Table 165. Mycoplasma Pneumoniae Antibodies Customers List Table 166. Mycoplasma Pneumoniae Antibodies Industry Trends Table 167. Mycoplasma Pneumoniae Antibodies Industry Drivers Table 168. Mycoplasma Pneumoniae Antibodies Industry Restraints Table 169. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Mycoplasma Pneumoniae Antibodies Product Image Figure 5. Global Mycoplasma Pneumoniae Antibodies Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Mycoplasma Pneumoniae Antibodies Market Size (2021-2032) & (US$ Million) Figure 7. Global Mycoplasma Pneumoniae Antibodies Sales (2021-2032) & (L) Figure 8. Global Mycoplasma Pneumoniae Antibodies Average Price (US$/L) & (2021-2032) Figure 9. Polyclonal Product Image Figure 10. Monoclonal Product Image Figure 11. Research Institutes Product Image Figure 12. Hospitals & Diagnostic Laboratories Product Image Figure 13. Pharmaceutical & Biotechnology Product Image Figure 14. Others Product Image Figure 15. Global Mycoplasma Pneumoniae Antibodies Revenue Share by Manufacturers in 2025 Figure 16. Global Manufacturers of Mycoplasma Pneumoniae Antibodies, Manufacturing Sites & Headquarters Figure 17. Global Top 5 and 10 Mycoplasma Pneumoniae Antibodies Players Market Share by Revenue in 2025 Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Mycoplasma Pneumoniae Antibodies Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 20. Global Mycoplasma Pneumoniae Antibodies Sales by Region in 2025 Figure 21. Global Mycoplasma Pneumoniae Antibodies Revenue by Region in 2025 Figure 22. North America Mycoplasma Pneumoniae Antibodies Market Size by Country in 2025 Figure 23. North America Mycoplasma Pneumoniae Antibodies Sales Market Share by Country (2021-2032) Figure 24. North America Mycoplasma Pneumoniae Antibodies Revenue Market Share by Country (2021-2032) Figure 25. United States Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Canada Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Mycoplasma Pneumoniae Antibodies Market Size by Country in 2025 Figure 28. Europe Mycoplasma Pneumoniae Antibodies Sales Market Share by Country (2021-2032) Figure 29. Europe Mycoplasma Pneumoniae Antibodies Revenue Market Share by Country (2021-2032) Figure 30. Germany Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Netherlands Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Asia Pacific Mycoplasma Pneumoniae Antibodies Market Size by Country in 2025 Figure 36. Asia Pacific Mycoplasma Pneumoniae Antibodies Sales Market Share by Country (2021-2032) Figure 37. Asia Pacific Mycoplasma Pneumoniae Antibodies Revenue Market Share by Country (2021-2032) Figure 38. China Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Japan Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. South Korea Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. India Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Australia Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. China Taiwan Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Southeast Asia Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Southeast Asia Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South America Mycoplasma Pneumoniae Antibodies Market Size by Country in 2025 Figure 47. South America Mycoplasma Pneumoniae Antibodies Sales Market Share by Country (2021-2032) Figure 48. South America Mycoplasma Pneumoniae Antibodies Revenue Market Share by Country (2021-2032) Figure 49. Mexico Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Brazil Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Argentina Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Colombia Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Middle East and Africa Mycoplasma Pneumoniae Antibodies Market Size by Country in 2025 Figure 54. Middle East and Africa Mycoplasma Pneumoniae Antibodies Sales Market Share by Country (2021-2032) Figure 55. Middle East and Africa Mycoplasma Pneumoniae Antibodies Revenue Market Share by Country (2021-2032) Figure 56. Turkey Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Saudi Arabia Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. UAE Mycoplasma Pneumoniae Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Global Mycoplasma Pneumoniae Antibodies Sales Market Share by Type (2021-2032) Figure 60. Global Mycoplasma Pneumoniae Antibodies Revenue Market Share by Type (2021-2032) Figure 61. Global Mycoplasma Pneumoniae Antibodies Price (US$/L) by Type (2021-2032) Figure 62. Global Mycoplasma Pneumoniae Antibodies Sales Market Share by Application (2021-2032) Figure 63. Global Mycoplasma Pneumoniae Antibodies Revenue Market Share by Application (2021-2032) Figure 64. Global Mycoplasma Pneumoniae Antibodies Price (US$/L) by Application (2021-2032) Figure 65. Mycoplasma Pneumoniae Antibodies Value Chain Figure 66. Mycoplasma Pneumoniae Antibodies Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Mycoplasma Pneumoniae Antibodies Industry Opportunities and Challenges

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Research Institutes
  • Hospitals & Diagnostic Laboratories
  • Pharmaceutical & Biotechnology
  • Others
Companies covered
  • Abbexa Ltd
  • Abcam
  • Abnova Corporation
  • American Research Products Inc.
  • Bio-Rad
  • Biorbyt
  • Creative Biolabs
  • EastCoast Bio
  • Fitzgerald Industries International
  • GeneTex
  • GRP GmbH
  • LifeSpan BioSciences
  • MyBioSource.com
  • Novus Biologicals
  • OriGene Technologies
  • ProSci, Inc
  • United States Biological
  • Thermo Fisher Scientific

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Mycoplasma Pneumoniae Antibodies Market Size (2021-2032)
  4. 2.2.2 Global Mycoplasma Pneumoniae Antibodies Sales (2021-2032)
  5. 2.2.3 Global Mycoplasma Pneumoniae Antibodies Market Average Price (2021-2032)
  6. 2.3 Mycoplasma Pneumoniae Antibodies by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Polyclonal
  9. 2.3.3 Monoclonal
  10. 2.4 Mycoplasma Pneumoniae Antibodies by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Research Institutes
  13. 2.4.3 Hospitals & Diagnostic Laboratories
  14. 2.4.4 Pharmaceutical & Biotechnology
  15. 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Mycoplasma Pneumoniae Antibodies Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Mycoplasma Pneumoniae Antibodies Sales (L) of Manufacturers (2021-2026)
  3. 3.3 Global Mycoplasma Pneumoniae Antibodies Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Mycoplasma Pneumoniae Antibodies Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Mycoplasma Pneumoniae Antibodies Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Mycoplasma Pneumoniae Antibodies, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Mycoplasma Pneumoniae Antibodies, Product Type & Application
  8. 3.8 Global Manufacturers of Mycoplasma Pneumoniae Antibodies, Established Date
  9. 3.9 Global Mycoplasma Pneumoniae Antibodies Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Abbexa Ltd
  2. 4.1.1 Abbexa Ltd Company Information
  3. 4.1.2 Abbexa Ltd Business Overview
  4. 4.1.3 Abbexa Ltd Mycoplasma Pneumoniae Antibodies Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Abbexa Ltd Mycoplasma Pneumoniae Antibodies Product Portfolio
  6. 4.1.5 Abbexa Ltd Recent Developments
  7. 4.2 Abcam
  8. 4.2.1 Abcam Company Information
  9. 4.2.2 Abcam Business Overview
  10. 4.2.3 Abcam Mycoplasma Pneumoniae Antibodies Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Abcam Mycoplasma Pneumoniae Antibodies Product Portfolio
  12. 4.2.5 Abcam Recent Developments
  13. 4.3 Abnova Corporation
  14. 4.3.1 Abnova Corporation Company Information
  15. 4.3.2 Abnova Corporation Business Overview
  16. 4.3.3 Abnova Corporation Mycoplasma Pneumoniae Antibodies Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Abnova Corporation Mycoplasma Pneumoniae Antibodies Product Portfolio
  18. 4.3.5 Abnova Corporation Recent Developments
  19. 4.4 American Research Products Inc.
  20. 4.4.1 American Research Products Inc. Company Information
  21. 4.4.2 American Research Products Inc. Business Overview
  22. 4.4.3 American Research Products Inc. Mycoplasma Pneumoniae Antibodies Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 American Research Products Inc. Mycoplasma Pneumoniae Antibodies Product Portfolio
  24. 4.4.5 American Research Products Inc. Recent Developments
  25. 4.5 Bio-Rad
  26. 4.5.1 Bio-Rad Company Information
  27. 4.5.2 Bio-Rad Business Overview
  28. 4.5.3 Bio-Rad Mycoplasma Pneumoniae Antibodies Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Bio-Rad Mycoplasma Pneumoniae Antibodies Product Portfolio
  30. 4.5.5 Bio-Rad Recent Developments
  31. 4.6 Biorbyt
  32. 4.6.1 Biorbyt Company Information
  33. 4.6.2 Biorbyt Business Overview
  34. 4.6.3 Biorbyt Mycoplasma Pneumoniae Antibodies Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Biorbyt Mycoplasma Pneumoniae Antibodies Product Portfolio
  36. 4.6.5 Biorbyt Recent Developments
  37. 4.7 Creative Biolabs
  38. 4.7.1 Creative Biolabs Company Information
  39. 4.7.2 Creative Biolabs Business Overview
  40. 4.7.3 Creative Biolabs Mycoplasma Pneumoniae Antibodies Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Creative Biolabs Mycoplasma Pneumoniae Antibodies Product Portfolio
  42. 4.7.5 Creative Biolabs Recent Developments
  43. 4.8 EastCoast Bio
  44. 4.8.1 EastCoast Bio Company Information
  45. 4.8.2 EastCoast Bio Business Overview
  46. 4.8.3 EastCoast Bio Mycoplasma Pneumoniae Antibodies Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 EastCoast Bio Mycoplasma Pneumoniae Antibodies Product Portfolio
  48. 4.8.5 EastCoast Bio Recent Developments
  49. 4.9 Fitzgerald Industries International
  50. 4.9.1 Fitzgerald Industries International Company Information
  51. 4.9.2 Fitzgerald Industries International Business Overview
  52. 4.9.3 Fitzgerald Industries International Mycoplasma Pneumoniae Antibodies Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Fitzgerald Industries International Mycoplasma Pneumoniae Antibodies Product Portfolio
  54. 4.9.5 Fitzgerald Industries International Recent Developments
  55. 4.10 GeneTex
  56. 4.10.1 GeneTex Company Information
  57. 4.10.2 GeneTex Business Overview
  58. 4.10.3 GeneTex Mycoplasma Pneumoniae Antibodies Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 GeneTex Mycoplasma Pneumoniae Antibodies Product Portfolio
  60. 4.10.5 GeneTex Recent Developments
  61. 4.11 GRP GmbH
  62. 4.11.1 GRP GmbH Company Information
  63. 4.11.2 GRP GmbH Business Overview
  64. 4.11.3 GRP GmbH Mycoplasma Pneumoniae Antibodies Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 GRP GmbH Mycoplasma Pneumoniae Antibodies Product Portfolio
  66. 4.11.5 GRP GmbH Recent Developments
  67. 4.12 LifeSpan BioSciences
  68. 4.12.1 LifeSpan BioSciences Company Information
  69. 4.12.2 LifeSpan BioSciences Business Overview
  70. 4.12.3 LifeSpan BioSciences Mycoplasma Pneumoniae Antibodies Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 LifeSpan BioSciences Mycoplasma Pneumoniae Antibodies Product Portfolio
  72. 4.12.5 LifeSpan BioSciences Recent Developments
  73. 4.13 MyBioSource.com
  74. 4.13.1 MyBioSource.com Company Information
  75. 4.13.2 MyBioSource.com Business Overview
  76. 4.13.3 MyBioSource.com Mycoplasma Pneumoniae Antibodies Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 MyBioSource.com Mycoplasma Pneumoniae Antibodies Product Portfolio
  78. 4.13.5 MyBioSource.com Recent Developments
  79. 4.14 Novus Biologicals
  80. 4.14.1 Novus Biologicals Company Information
  81. 4.14.2 Novus Biologicals Business Overview
  82. 4.14.3 Novus Biologicals Mycoplasma Pneumoniae Antibodies Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Novus Biologicals Mycoplasma Pneumoniae Antibodies Product Portfolio
  84. 4.14.5 Novus Biologicals Recent Developments
  85. 4.15 OriGene Technologies
  86. 4.15.1 OriGene Technologies Company Information
  87. 4.15.2 OriGene Technologies Business Overview
  88. 4.15.3 OriGene Technologies Mycoplasma Pneumoniae Antibodies Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 OriGene Technologies Mycoplasma Pneumoniae Antibodies Product Portfolio
  90. 4.15.5 OriGene Technologies Recent Developments
  91. 4.16 ProSci, Inc
  92. 4.16.1 ProSci, Inc Company Information
  93. 4.16.2 ProSci, Inc Business Overview
  94. 4.16.3 ProSci, Inc Mycoplasma Pneumoniae Antibodies Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 ProSci, Inc Mycoplasma Pneumoniae Antibodies Product Portfolio
  96. 4.16.5 ProSci, Inc Recent Developments
  97. 4.17 United States Biological
  98. 4.17.1 United States Biological Company Information
  99. 4.17.2 United States Biological Business Overview
  100. 4.17.3 United States Biological Mycoplasma Pneumoniae Antibodies Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 United States Biological Mycoplasma Pneumoniae Antibodies Product Portfolio
  102. 4.17.5 United States Biological Recent Developments
  103. 4.18 Thermo Fisher Scientific
  104. 4.18.1 Thermo Fisher Scientific Company Information
  105. 4.18.2 Thermo Fisher Scientific Business Overview
  106. 4.18.3 Thermo Fisher Scientific Mycoplasma Pneumoniae Antibodies Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Thermo Fisher Scientific Mycoplasma Pneumoniae Antibodies Product Portfolio
  108. 4.18.5 Thermo Fisher Scientific Recent Developments
5 Global Mycoplasma Pneumoniae Antibodies Market Scenario by Region
  1. 5.1 Global Mycoplasma Pneumoniae Antibodies Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Mycoplasma Pneumoniae Antibodies Sales by Region: 2021-2032
  3. 5.2.1 Global Mycoplasma Pneumoniae Antibodies Sales by Region: 2021-2026
  4. 5.2.2 Global Mycoplasma Pneumoniae Antibodies Sales by Region: 2027-2032
  5. 5.3 Global Mycoplasma Pneumoniae Antibodies Revenue by Region: 2021-2032
  6. 5.3.1 Global Mycoplasma Pneumoniae Antibodies Revenue by Region: 2021-2026
  7. 5.3.2 Global Mycoplasma Pneumoniae Antibodies Revenue by Region: 2027-2032
  8. 5.4 North America Mycoplasma Pneumoniae Antibodies Market Facts & Figures by Country
  9. 5.4.1 North America Mycoplasma Pneumoniae Antibodies Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Mycoplasma Pneumoniae Antibodies Sales by Country (2021-2032)
  11. 5.4.3 North America Mycoplasma Pneumoniae Antibodies Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Mycoplasma Pneumoniae Antibodies Market Facts & Figures by Country
  15. 5.5.1 Europe Mycoplasma Pneumoniae Antibodies Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Mycoplasma Pneumoniae Antibodies Sales by Country (2021-2032)
  17. 5.5.3 Europe Mycoplasma Pneumoniae Antibodies Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Mycoplasma Pneumoniae Antibodies Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Mycoplasma Pneumoniae Antibodies Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Mycoplasma Pneumoniae Antibodies Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Mycoplasma Pneumoniae Antibodies Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Mycoplasma Pneumoniae Antibodies Market Facts & Figures by Country
  35. 5.7.1 South America Mycoplasma Pneumoniae Antibodies Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Mycoplasma Pneumoniae Antibodies Sales by Country (2021-2032)
  37. 5.7.3 South America Mycoplasma Pneumoniae Antibodies Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.7.7 Colombia
  42. 5.8 Middle East and Africa Mycoplasma Pneumoniae Antibodies Market Facts & Figures by Country
  43. 5.8.1 Middle East and Africa Mycoplasma Pneumoniae Antibodies Market Size by Country: 2021 VS 2025 VS 2032
  44. 5.8.2 Middle East and Africa Mycoplasma Pneumoniae Antibodies Sales by Country (2021-2032)
  45. 5.8.3 Middle East and Africa Mycoplasma Pneumoniae Antibodies Revenue by Country (2021-2032)
  46. 5.8.4 Turkey
  47. 5.8.5 Saudi Arabia
  48. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Mycoplasma Pneumoniae Antibodies Sales by Type (2021-2032)
  2. 6.1.1 Global Mycoplasma Pneumoniae Antibodies Sales by Type (2021-2032) & (L)
  3. 6.1.2 Global Mycoplasma Pneumoniae Antibodies Sales Market Share by Type (2021-2032)
  4. 6.2 Global Mycoplasma Pneumoniae Antibodies Revenue by Type (2021-2032)
  5. 6.2.1 Global Mycoplasma Pneumoniae Antibodies Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Mycoplasma Pneumoniae Antibodies Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Mycoplasma Pneumoniae Antibodies Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Mycoplasma Pneumoniae Antibodies Sales by Application (2021-2032)
  2. 7.1.1 Global Mycoplasma Pneumoniae Antibodies Sales by Application (2021-2032) & (L)
  3. 7.1.2 Global Mycoplasma Pneumoniae Antibodies Sales Market Share by Application (2021-2032)
  4. 7.2 Global Mycoplasma Pneumoniae Antibodies Revenue by Application (2021-2032)
  5. 7.2.1 Global Mycoplasma Pneumoniae Antibodies Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Mycoplasma Pneumoniae Antibodies Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Mycoplasma Pneumoniae Antibodies Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Mycoplasma Pneumoniae Antibodies Value Chain Analysis
  2. 8.1.1 Mycoplasma Pneumoniae Antibodies Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Mycoplasma Pneumoniae Antibodies Production Mode & Process
  5. 8.2 Mycoplasma Pneumoniae Antibodies Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Mycoplasma Pneumoniae Antibodies Distributors
  8. 8.2.3 Mycoplasma Pneumoniae Antibodies Customers
9 Global Mycoplasma Pneumoniae Antibodies Analyzing Market Dynamics
  1. 9.1 Mycoplasma Pneumoniae Antibodies Industry Trends
  2. 9.2 Mycoplasma Pneumoniae Antibodies Industry Drivers
  3. 9.3 Mycoplasma Pneumoniae Antibodies Industry Opportunities and Challenges
  4. 9.4 Mycoplasma Pneumoniae Antibodies Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst